Posts by Mourabit Halima

In the treatment landscape of HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) have become a widely used first-line treatment. However, patients with symptomatic visceral metastases often opt for chemotherapy (CT). While some prospective studies suggest that CDK4/6i + ET may yield better outcomes even in patients with visceral metastases, no studies have explored these strategies in real-world settings.

The 47th San Antonio Breast Cancer Symposium (SABCS) is in full swing in San Antonio, USA, showcasing cutting-edge research from around the world. On December 12 (Central Time), during the “Poster Spotlight – Session 8: Novel HER2 Therapeutics”, Dr. Biyun Wang and her team from Fudan University Shanghai Cancer Center presented their groundbreaking findings on GQ1005, a highly promising HER2 antibody-drug conjugate (ADC). The study’s evaluation of GQ1005’s efficacy and safety in HER2-positive metastatic breast cancer (MBC) patients drew significant attention, leading to vibrant discussions among experts. Dr. Wang provides an in-depth interpretation of this important research.

From December 10 to 13, 2024, the 47th San Antonio Breast Cancer Symposium (SABCS) took place in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in the field of breast cancer research, SABCS showcased the latest findings, clinical practices, treatment advancements, and technological innovations from the past year.Among the many noteworthy contributions, a study by Dr. Yunjian Liu's team from The Fourth Hospital of Hebei Medical University stood out. Their research focused on the prognostic value of ctDNA monitoring in breast cancer patients undergoing neoadjuvant therapy and was presented as a poster (Abstract No. P3-05-22). The study highlights how personalized ctDNA testing can dynamically monitor minimal residual disease (MRD), predict treatment efficacy and recurrence risk, and provide valuable insights for clinical decision-making. Oncology Frontier interviewed Professor Liu onsite for an in-depth discussion.

On December 6, CAHON brought together a distinguished group of hematology and oncology experts at The University Club Atop Symphony Tower in San Diego, CA. The symposium was a celebration of collaboration, innovation, and mentorship.

The 47th San Antonio Breast Cancer Symposium (SABCS), held from December 10–13, 2024, in San Antonio, USA, showcased the latest research, clinical practices, and technological innovations in breast cancer. In this special installment of the “Highlights Series,” hosted by Prof. Yongmei Yin of Jiangsu Provincial People’s Hospital, Prof. Qiang Liu from the Sun Yat-sen Memorial Hospital joins us live from SABCS to present significant immunotherapy findings unveiled on the final day of the conference (December 13). These include updates on the ZEST, CamRelief, NSABP B-59/GBG-96-GeparDouze, A-BRAVE, and BreastImmune-03 studies for triple-negative breast cancer (TNBC), as well as insights into HER2-positive breast cancer from the NRG-BR004 and neoHIP trials.

Advances in medical oncology for breast cancer are reshaping the approach to drug dosing and regimen design. Traditional chemotherapy development relied heavily on identifying the maximum tolerated dose (MTD)—the highest dose patients could endure without severe side effects. However, the focus in modern drug development, particularly for molecular targeted therapies, is shifting toward individualized dose optimization strategies. On December 10 (Tuesday) from 2:00 to 3:45 PM (CST), experts at the 2024 San Antonio Breast Cancer Symposium delved into these strategies during the "Clinical Symposium on Dose Optimization in Breast Oncology."